Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis

This article was originally published in Scrip

Executive Summary

Amgen Inc.'s Kyprolis (carfilzomib) has been given the green light in Europe for the treatment of relapsed multiple myeloma, after being pushed through reviews under the European Medicines Agency's accelerated assessment program.

You may also be interested in...



Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant

Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.

Snapshot: August Highlights

A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.

‘Translators’ Will Form The Next Generation Of Biopharma Leaders

Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel